1887
Rapid communication Open Access
Like 0

Abstract

The South Korea mass vaccination programme administered 3.8 million doses of COVID-19 vaccinations between 26 February and 30 April 2021. After 173 suspected anaphylaxis reports to the nationwide monitoring system for adverse events following immunisation, 44 anaphylaxis cases were confirmed using Brighton Collaboration case definitions. The rates per million doses were 18.2 cases and 6.2 cases for Vaxzevria and Comirnaty, respectively. Median time of onset was 14 min after vaccination and most cases had recovered at the time of review.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2021.26.33.2100694
2021-08-19
2021-09-21
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2021.26.33.2100694
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/26/33/eurosurv-26-33-1.html?itemId=/content/10.2807/1560-7917.ES.2021.26.33.2100694&mimeType=html&fmt=ahah

References

  1. Law B. SO2- D2.5.2.1 AESI case definition companion guide for 1st Tier AESI – Anaphylaxis. Safety Platform for Emergency vACcines. Ponce de Leon: The Task Force for Global Health; 2021. Available from: https://brightoncollaboration.us/wp-content/uploads/2021/03/SPEAC_D2.5.2.1_Anaphylaxis-Case-Definition-Companion-Guide_V1.0-12070-1.pdf
  2. Korea Disease Control and Prevention Agency (KDCA). Update on COVID-19 and COVID-19 vaccination. Press release. Cheongju-si: KDCA; 12 Apr 2021. Korean. Available from: http://ncov.mohw.go.kr/tcmBoardView.do?brdId=3&brdGubun=31&dataGubun=&ncvContSeq=5162&contSeq=5162&board_id=312&gubun=ALL
  3. European Medicines Agency (EMA). Press briefing on the conclusion of the assessment of the Pharmacovigilance Risk Assessment Committee (PRAC) of Vaxzevria (previously COVID-19 Vaccine AstraZeneca) and thromboembolic events. Press release. Amsterdam: EMA; 7 Apr 2021. Available from: https://www.ema.europa.eu/en/events/press-briefing-conclusion-assessment-pharmacovigilance-risk-assessment-committee-prac-vaxzevria
  4. Korea Disease Control and Prevention Agency (KDCA). Adverse events following COVID-19 immunization management guidelines. Cheongju-si: KDCA; 2021. Korean. Available from: https://ncv.kdca.go.kr/board.es?mid=a12101000000&bid=0031#content
  5. Jeong J. Treatment and management of anaphylaxis. J of the Korea. 2014;57(11):934-40.
  6. MHRA. Coronavirus vaccine - weekly summary of Yellow Card reporting, Medicines& Healthcare products Regulatory Agency(MHRA). 2021. Available from: https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting
  7. CDC COVID-19 Response TeamFood and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine - United States, December 14-23, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(2):46-51.  https://doi.org/10.15585/mmwr.mm7002e1  PMID: 33444297 
  8. CDC COVID-19 Response TeamFood and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine — United States, December 21, 2020-January 10, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(4):125-9.  https://doi.org/10.15585/mmwr.mm7004e1  PMID: 33507892 
  9. The advisory committee on coagulation disorders. Risk and benefit of AstraZeneca vaccination regarding to Thrombosis with thrombocytopenia. PHWR. 2021;14(17):988-96.
  10. Shimabukuro TT, Cole M, Su JR. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US—December 14, 2020-January 18, 2021. JAMA. 2021;325(11):1101-2.  https://doi.org/10.1001/jama.2021.1967  PMID: 33576785 
/content/10.2807/1560-7917.ES.2021.26.33.2100694
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error